Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T70176
|
||||
Former ID |
TTDC00088
|
||||
Target Name |
Cell division protein kinase 2
|
||||
Gene Name |
CDK2
|
||||
Synonyms |
Cyclin-dependent kinase 2; P33 protein kinase; SIN3-associated protein; Sin3 associated polypeptide; CDK2
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Advanced solid tumor [ICD9: 140-199; ICD10: C00-C75, C7A, C7B] | ||||
Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Hematological malignancies [ICD9: 200-209; ICD10: C81-C86] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Retinoblastoma [ICD10: C69.2] | |||||
Small-cell lung cancer [ICD9: 162.9; ICD10: C33-C34] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Thymoma [ICD9: 164.0, 212.6; ICD10: C37, D15.0] | |||||
Function |
Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2. Interacts with cyclins A, B1, B3, D, or E. Triggers duplication of centrosomes and DNA. Acts at the G1-S transition to promote the E2F transcriptional program and the initiation ofDNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus. Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in human embryonic stem cells (hESCs). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2(cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase. EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing. Phosphorylates CABLES1 (By similarity). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC. Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis. In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation. Phosphorylation of RB1 disturbs its interaction with E2F1. NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication. Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT- mediated activation of histone gene transcription during S phase. Required for vitamin D-mediated growth inhibition by being itself inactivated. Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner. USP37 is activated by phosphorylation and thus triggers G1-S transition. CTNNB1 phosphorylation regulates insulin internalization.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T70176
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.11.22
|
||||
Sequence |
MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNH
PNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHS HRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYY STAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSF PKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL |
||||
Drugs and Mode of Action | |||||
Drug(s) | PHA848125 | Drug Info | Phase 2 | Thymoma | [522850], [542853] |
R-roscovitine | Drug Info | Phase 2 | Cancer | [524796] | |
Ro 31-7453 | Drug Info | Phase 2 | Solid tumours | [531583] | |
Seliciclib | Drug Info | Phase 2 | Non-small cell lung cancer | [541292], [546752] | |
AG-024322 | Drug Info | Phase 1 | Cancer | [537564] | |
AZD-5438 | Drug Info | Phase 1 | Solid tumours | [530197], [543159] | |
PHA-793887 | Drug Info | Phase 1 | Cancer | [531377] | |
RGB-286638 | Drug Info | Phase 1 | Hematological malignancies | [523121], [542709] | |
SNS-032 | Drug Info | Phase 1 | Solid tumours | [537097], [541014] | |
TG02 | Drug Info | Phase 1 | Cancer | [531820] | |
INOC-005 | Drug Info | Preclinical | Cancer | [548139] | |
Capridine-beta | Drug Info | Discontinued in Phase 4 | Psoriasis | [533123] | |
SCH 727965 | Drug Info | Discontinued in Phase 3 | Acute lymphoblastic leukemia | [531565], [533028], [542400] | |
AT7519 | Drug Info | Discontinued in Phase 2 | Solid tumours | [530659], [530723], [541006] | |
BAY 10-00394 | Drug Info | Discontinued in Phase 2 | Small-cell lung cancer | [531973], [542800] | |
R547 | Drug Info | Discontinued in Phase 1 | Advanced solid tumor | [541047], [547737] | |
ZK 304709 | Drug Info | Discontinued in Phase 1 | Advanced solid tumor | [548143] | |
Olomoucine | Drug Info | Terminated | Discovery agent | [546498] | |
PD-0183812 | Drug Info | Terminated | Retinoblastoma | [547217] | |
Inhibitor | (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime | Drug Info | [530823] | ||
(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime | Drug Info | [530823] | |||
(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime | Drug Info | [530823] | |||
1-Amino-6-Cyclohex-3-Enylmethyloxypurine | Drug Info | [551393] | |||
2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol | Drug Info | [528490] | |||
2-Amino-6-Chloropyrazine | Drug Info | [551393] | |||
2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE | Drug Info | [551374] | |||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3,4-diphenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol | Drug Info | [528490] | |||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine | Drug Info | [551393] | |||
4-(7-Butyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenol | Drug Info | [526504] | |||
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol | Drug Info | [528490] | |||
4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide | Drug Info | [551374] | |||
4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline | Drug Info | [551391] | |||
5-hydroxynaphthalene-1-sulfonamide | Drug Info | [551374] | |||
5-nitroindirubin-3'-oxime | Drug Info | [530823] | |||
6-(3-Amino-benzyloxy)-9H-purin-2-ylamine | Drug Info | [526389] | |||
6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine | Drug Info | [526389] | |||
6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine | Drug Info | [526389] | |||
6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE | Drug Info | [551374] | |||
6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine | Drug Info | [526489] | |||
6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE | Drug Info | [551374] | |||
6-O-Cyclohexylmethyl Guanine | Drug Info | [551393] | |||
AG-024322 | Drug Info | [537564] | |||
aloisine | Drug Info | [531779] | |||
aloisine A | Drug Info | [526504] | |||
Alsterpaullone | Drug Info | [535564] | |||
Aminopurvalanol | Drug Info | [535564] | |||
aminopurvalanol A | Drug Info | [529213] | |||
AT7519 | Drug Info | [537034] | |||
BAY 10-00394 | Drug Info | [550520] | |||
Benzyl-(9-isopropyl-9H-purin-6-yl)-amine | Drug Info | [525825] | |||
BMS-265246 | Drug Info | [531328] | |||
BMS-536924 | Drug Info | [527711] | |||
BOHEMINE | Drug Info | [525825] | |||
BX-795 | Drug Info | [527484] | |||
BX-912 | Drug Info | [527484] | |||
Capridine-beta | Drug Info | [551434] | |||
Cdk1/2 inhibitor III | Drug Info | [527600] | |||
CDK2 inhibitors | Drug Info | [543528] | |||
Cdk4 inhibitor III | Drug Info | [525734] | |||
compound 3 | Drug Info | [529880] | |||
compound 89S | Drug Info | [529892] | |||
compound 9b | Drug Info | [529792] | |||
CVT-313 | Drug Info | [543528] | |||
Double Oxidized Cysteine | Drug Info | [551393] | |||
GW-8510 | Drug Info | [526991] | |||
Hymenialdisine | Drug Info | [535564] | |||
Indirubin-3'-monoxime | Drug Info | [535564] | |||
Indirubin-5-sulfonate | Drug Info | [535564] | |||
INOC-005 | Drug Info | [530064] | |||
JNJ-7706621 | Drug Info | [528188] | |||
K00024 | Drug Info | [526625] | |||
Lysine Nz-Carboxylic Acid | Drug Info | [551393] | |||
MERIOLIN 1 | Drug Info | [529275] | |||
MERIOLIN 2 | Drug Info | [529275] | |||
MERIOLIN 3 | Drug Info | [529275] | |||
MERIOLIN 4 | Drug Info | [529275] | |||
MERIOLIN 5 | Drug Info | [529275] | |||
MERIOLIN 6 | Drug Info | [529275] | |||
MERIOLIN 8 | Drug Info | [529275] | |||
N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE | Drug Info | [551374] | |||
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide | Drug Info | [528237] | |||
N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide | Drug Info | [551374] | |||
N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide | Drug Info | [551393] | |||
N-phenyl-1H-pyrazole-3-carboxamide | Drug Info | [551374] | |||
NSC-625987 | Drug Info | [525671] | |||
NU-2058 | Drug Info | [528372] | |||
NU-6027 | Drug Info | [526489] | |||
NU-6086 | Drug Info | [530065] | |||
NU-6094 | Drug Info | [530065] | |||
NU-6102 | Drug Info | [528404] | |||
NU6140 | Drug Info | [527749] | |||
Olomoucine | Drug Info | [535564] | |||
Oxindole 95 | Drug Info | [535564] | |||
PD-0183812 | Drug Info | [525924] | |||
PF-228 | Drug Info | [528764] | |||
PHA-690509 | Drug Info | [531076] | |||
PHA-793887 | Drug Info | [531377] | |||
PHA848125 | Drug Info | [530259], [530591] | |||
PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE | Drug Info | [551374] | |||
Purvalanol B | Drug Info | [535564] | |||
PURVALANOLA | Drug Info | [529039] | |||
PYRAZOLOPYRIDAZINE 1 | Drug Info | [527192] | |||
PYRAZOLOPYRIDAZINE 2 | Drug Info | [527192] | |||
R-roscovitine | Drug Info | [537564] | |||
R547 | Drug Info | [537564] | |||
RESCOVITINE | Drug Info | [530612] | |||
RGB-286638 | Drug Info | [532412] | |||
Ro 31-7453 | Drug Info | [536474] | |||
SCH 727965 | Drug Info | [537564] | |||
SCH-546909 | Drug Info | [543528] | |||
Seliciclib | Drug Info | [536474], [537636] | |||
SNS-032 | Drug Info | [537097], [537228] | |||
SU9516 | Drug Info | [535564] | |||
TRIAZOLOPYRIMIDINE | Drug Info | [551374] | |||
VER-54505 | Drug Info | [543528] | |||
ZK 304709 | Drug Info | [537564] | |||
Modulator | AZD-5438 | Drug Info | [530197] | ||
TG02 | Drug Info | [531820] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | FoxO signaling pathway | ||||
Cell cycle | |||||
Oocyte meiosis | |||||
p53 signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
Progesterone-mediated oocyte maturation | |||||
Hepatitis B | |||||
Measles | |||||
Herpes simplex infection | |||||
Epstein-Barr virus infection | |||||
Pathways in cancer | |||||
Viral carcinogenesis | |||||
Prostate cancer | |||||
Small cell lung cancer | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | p53 pathway | ||||
p53 pathway feedback loops 2 | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by PRL | |||||
p73 transcription factor network | |||||
E2F transcription factor network | |||||
ATR signaling pathway | |||||
mTOR signaling pathway | |||||
IL2-mediated signaling events | |||||
FoxO family signaling | |||||
FOXM1 transcription factor network | |||||
BARD1 signaling events | |||||
p53 pathway | |||||
Regulation of retinoblastoma protein | |||||
Reactome | G0 and Early G1 | ||||
Activation of ATR in response to replication stress | |||||
Regulation of APC/C activators between G1/S and early anaphase | |||||
SCF(Skp2)-mediated degradation of p27/p21 | |||||
Senescence-Associated Secretory Phenotype (SASP) | |||||
DNA Damage/Telomere Stress Induced Senescence | |||||
Processing of DNA double-strand break ends | |||||
G2 Phase | |||||
Orc1 removal from chromatin | |||||
Cyclin E associated events during G1/S transition | |||||
Cyclin A/B1 associated events during G2/M transition | |||||
p53-Dependent G1 DNA Damage Response | |||||
Cdk2-associated events at S phase entry | |||||
Meiotic recombination | |||||
Factors involved in megakaryocyte development and platelet production | |||||
WikiPathways | DNA Damage Response | ||||
ID signaling pathway | |||||
DNA Replication | |||||
G1 to S cell cycle control | |||||
M/G1 Transition | |||||
S Phase | |||||
Meiotic Recombination | |||||
Aryl Hydrocarbon Receptor | |||||
ATM Signaling Pathway | |||||
Retinoblastoma (RB) in Cancer | |||||
Spinal Cord Injury | |||||
Integrated Pancreatic Cancer Pathway | |||||
Oncostatin M Signaling Pathway | |||||
Prostate Cancer | |||||
Signaling Pathways in Glioblastoma | |||||
TSH signaling pathway | |||||
Integrated Breast Cancer Pathway | |||||
Integrated Cancer pathway | |||||
Synthesis of DNA | |||||
Regulation of DNA replication | |||||
Mitotic G2-G2/M phases | |||||
Mitotic G1-G1/S phases | |||||
Factors involved in megakaryocyte development and platelet production | |||||
Cell Cycle | |||||
APC/C-mediated degradation of cell cycle proteins | |||||
Cell Cycle Checkpoints | |||||
miRNA Regulation of DNA Damage Response | |||||
References | |||||
Ref 522850 | ClinicalTrials.gov (NCT01011439) Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma. U.S. National Institutes of Health. | ||||
Ref 523121 | ClinicalTrials.gov (NCT01168882) Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies. U.S. National Institutes of Health. | ||||
Ref 524796 | ClinicalTrials.gov (NCT02160730) Treatment of Cushing's Disease With R-roscovitine. U.S. National Institutes of Health. | ||||
Ref 530197 | AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. | ||||
Ref 530659 | AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36. | ||||
Ref 530723 | Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem. 2010 Mar 1;18(5):1844-53. | ||||
Ref 531377 | A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15. | ||||
Ref 531565 | Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1. | ||||
Ref 531583 | A phase 2 study of oral MKC-1, an inhibitor of importin-beta, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug;30(4):1614-20. | ||||
Ref 531820 | Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42. | ||||
Ref 531973 | BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Mol Cancer Ther. 2012 Oct;11(10):2265-73. | ||||
Ref 533028 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8. | ||||
Ref 537097 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. Epub 2009 Feb 20. | ||||
Ref 537564 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | ||||
Ref 541006 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5662). | ||||
Ref 541014 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5670). | ||||
Ref 541047 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5707). | ||||
Ref 541292 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6035). | ||||
Ref 542400 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7379). | ||||
Ref 542709 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7744). | ||||
Ref 542800 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7874). | ||||
Ref 542853 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7938). | ||||
Ref 543159 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8473). | ||||
Ref 546498 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008577) | ||||
Ref 546752 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010117) | ||||
Ref 547217 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130) | ||||
Ref 547737 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018924) | ||||
Ref 525671 | The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86. | ||||
Ref 525734 | 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. | ||||
Ref 525825 | J Med Chem. 2000 Jun 29;43(13):2506-13.Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. | ||||
Ref 525924 | J Med Chem. 2000 Nov 30;43(24):4606-16.Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. | ||||
Ref 526389 | J Med Chem. 2002 Aug 1;45(16):3381-93.Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. | ||||
Ref 526489 | Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22.4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. | ||||
Ref 526504 | J Med Chem. 2003 Jan 16;46(2):222-36.Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. | ||||
Ref 526625 | Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. | ||||
Ref 526991 | Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7.Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. | ||||
Ref 527192 | J Med Chem. 2004 Sep 9;47(19):4716-30.N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. | ||||
Ref 527484 | Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. Epub 2005 Mar 16. | ||||
Ref 527600 | 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. | ||||
Ref 527711 | J Med Chem. 2005 Sep 8;48(18):5639-43.Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. | ||||
Ref 527749 | Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. | ||||
Ref 528032 | J Med Chem. 2006 Feb 23;49(4):1271-81.Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. | ||||
Ref 528188 | Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6.Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. | ||||
Ref 528237 | J Med Chem. 2006 Jun 15;49(12):3563-80.Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. | ||||
Ref 528372 | J Med Chem. 2006 Aug 24;49(17):5141-53.Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations. | ||||
Ref 528404 | J Med Chem. 2006 Sep 7;49(18):5470-7.Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. | ||||
Ref 528490 | J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. | ||||
Ref 528764 | J Biol Chem. 2007 May 18;282(20):14845-52. Epub 2007 Mar 28.Cellular characterization of a novel focal adhesion kinase inhibitor. | ||||
Ref 529039 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. | ||||
Ref 529213 | Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | ||||
Ref 529275 | J Med Chem. 2008 Feb 28;51(4):737-51. Epub 2008 Jan 31.Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolincomplex. | ||||
Ref 529792 | Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. Epub 2008 Oct 22.Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. | ||||
Ref 529880 | 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett. 2009 Feb 1;19(3):908-11. | ||||
Ref 529892 | First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. | ||||
Ref 530064 | What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15. | ||||
Ref 530065 | J Med Chem. 2009 May 14;52(9):2854-62.Halogen bonding--a novel interaction for rational drug design?. | ||||
Ref 530197 | AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol Cancer Ther. 2009 Jul;8(7):1856-66. | ||||
Ref 530259 | Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63. | ||||
Ref 530591 | The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol Res. 2010 May;61(5):437-48. | ||||
Ref 530612 | Eur J Med Chem. 2010 Mar;45(3):1158-66. Epub 2009 Dec 21.Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. | ||||
Ref 530823 | J Med Chem. 2010 May 13;53(9):3696-706.5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. | ||||
Ref 531076 | Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6. | ||||
Ref 531328 | A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54. | ||||
Ref 531377 | A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. Cell Cycle. 2011 Mar 15;10(6):963-70. Epub 2011 Mar 15. | ||||
Ref 531779 | Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39. | ||||
Ref 531820 | Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42. | ||||
Ref 532412 | Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. | ||||
Ref 535564 | Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. | ||||
Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
Ref 537034 | Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32. Epub 2009 Jan 27. | ||||
Ref 537097 | Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. Epub 2009 Feb 20. | ||||
Ref 537228 | Development of cell-cycle inhibitors for cancer therapy. Curr Oncol. 2009 Mar;16(2):36-43. | ||||
Ref 537564 | Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. | ||||
Ref 537636 | Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle. 2009 Sep 8;8(17). | ||||
Ref 543528 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973). | ||||
Ref 551391 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-4. Nucleic Acids Res. 2011 January |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.